Vasostrict®

About Vasostrict®

Vasostrict® Injection - Par launched Vasostrict® on Nov. 12, 2014. Par's Vasostrict is the first and only vasopressin injection, USP, product with an NDA approved by the FDA. Vasostrict is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. Vasostrict is packaged in cartons of 25 multi-dose vials each containing vasopressin 1 mL at 20 units/mL.

Important Safety Information

Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. Vasostrict is contraindicated in patients with known allergy or hypersensitivity to 8-L arginine vasopressin or chlorobutanol. Use in patents with impaired cardiac response may worsen cardiac output. The most common adverse reactions include decreases cardiac output, bradycardia, tachyarrhythmias, hyponatremia, and ischemia (coronary, mesenteric, skin, digital).

View the full Prescribing Information for Vasostrict®

For more information about Par Sterile Products, please Contact Us.